Lauren Sabella Net Worth

The estimated Net Worth of Lauren M Sabella is at least $3.04 Milione dollars as of 2 December 2019. Ms. Sabella owns over 1,513 units of Acorda Therapeutics Inc stock worth over $8,332 and over the last 14 years she sold ACOR stock worth over $2,107,221. In addition, she makes $921,983 as Chief Commercial Officer at Acorda Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Sabella ACOR stock SEC Form 4 insiders trading

Lauren has made over 18 trades of the Acorda Therapeutics Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently she sold 1,513 units of ACOR stock worth $2,421 on 2 December 2019.

The largest trade she's ever made was exercising 24,375 units of Acorda Therapeutics Inc stock on 8 June 2018 worth over $402,188. On average, Lauren trades about 2,722 units every 75 days since 2010. As of 2 December 2019 she still owns at least 12,624 units of Acorda Therapeutics Inc stock.

You can see the complete history of Ms. Sabella stock trades at the bottom of the page.

Lauren Sabella biography

Lauren M. Sabella is Chief Commercial Officer of Acorda Therapeutics, Inc. since February 2015. Prior to that, from January 2010 to February 2015, she was our Executive Vice President, Commercial Development. Ms. Sabella was the Founder and Principal of Tugboat Consulting Group, an independent consulting practice assisting companies in the commercialization process. Ms. Sabella also served as Corporate Officer and VP of Commercial Development at Altus Pharmaceuticals from May 2006 to September 2008, with responsibility for all aspects of commercialization. Prior to joining Altus, Ms. Sabella was employed by Boehringer Ingelheim Pharmaceuticals for 18 years in positions of increasing responsibility. In her last role, she served as VP of Sales, Eastern Zone, where she led the successful sales launch of Spiriva and ran both Primary Care and Specialty Divisions, including Neurology, Urology and Cardio/Pulmonary. Prior to this role, she had over ten years of marketing experience where she led several product launches including Mobic, an NSAID which became a $1 billion brand. Ms. Sabella holds a B.B.A. from Hofstra University.

What is the salary of Lauren Sabella?

As the Chief Commercial Officer of Acorda Therapeutics Inc, the total compensation of Lauren Sabella at Acorda Therapeutics Inc is $921,983. There are 3 executives at Acorda Therapeutics Inc getting paid more, with Ron Cohen having the highest compensation of $2,039,560.

How old is Lauren Sabella?

Lauren Sabella is 59, she's been the Chief Commercial Officer of Acorda Therapeutics Inc since 2015. There are 14 older and 2 younger executives at Acorda Therapeutics Inc. The oldest executive at Acorda Therapeutics Inc is Lorin Randall, 76, who is the Independent Director.

What's Lauren Sabella's mailing address?

Lauren's mailing address filed with the SEC is 1 CASPER STREET, , DANBURY, CT, 06810.

Insiders trading at Acorda Therapeutics Inc

Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith e Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.

What does Acorda Therapeutics Inc do?

acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate

Complete history of Ms. Sabella stock trades at Acorda Therapeutics Inc e Mannkind Corp

Acorda Therapeutics Inc executives and stock owners

Acorda Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ron Cohen,
  President,Chief Executive Officer, Director
• Dr. Ron Cohen M.D.,
  Founder, CEO, Pres & Director
• Burkhard Blank,
  Chief Medical Officer and Head of R&D
• Lauren Sabella,
  Chief Commercial Officer
• David Lawrence,
  Chief Business Operations, Principal Accounting Officer
• Dr. Burkhard Blank M.D.,
  Consultant
• Lauren M. Sabella,
  Chief Operating Officer
• Peder Jensen,
  Independent Director
• John Kelley,
  Non-Executive Independent Chairman of the Board
• Lorin Randall,
  Independent Director
• Sandra Panem,
  Independent Director
• Barry Greene,
  Independent Director
• Catherine Strader,
  Independent Director
• Neil S. Belloff Esq.,
  Gen. Counsel
• Michael A. Gesser M.B.A.,
  Chief Financial Officer
• Dr. Wise Young M.D., Ph.D.,
  Special Scientific Advisor
• Kerry M. Clem,
  Chief Commercial Officer
• Robert Morales,
  Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller
• Peter S. Carbone,
  Exec. VP of Quality
• Dr. Andrew R. Blight,
  Chief Scientific Officer Emeritus
• Denise J. Duca,
  Exec. VP of HR
• Tierney Saccavino,
  Exec. VP of Corp. Communications
• Andrew Mayer J.D.,
  Sr. VP, Deputy Gen. Counsel & Corp. Sec.
• Felicia Vonella,
  VP of Investor Relations
• Ian F Smith,
  Director
• Richard P. Batycky,
  Chief Tech. Off. & Site Head
• Steven M Rauscher,
  Director
• Capital Management Lp Scopi...,
  
• Kerry M Clem,
  Chief Commercial Officer
• Wise Young,
  Director
• Thomas Wessel,
  Chief Medical Officer
• Andrew A. Hindman,
  Chief Business Dev. Officer
• Barclay A Phillips,
  Director
• Capital Investments Ltd.Rid...,
  
• Mark R E Pinney,
  Director
• Michael Steinmetz,
  Director
• Standish Fleming,
  Director
• John H Friedman,
  Director
• Mary Fisher,
  Chief Operating Officer
• Michael W Rogers,
  Chief Financial Officer
• Enrique J. Carrazana,
  Chief Medical Officer
• Jane Wasman,
  President, Intl and GC
• Robert Morales,
  Interim PAO & PFO
• John Varian,
  Director
• Michael A Gesser,
  Chief Financial Officer
• Thomas M. Burns,
  Director
• Neil S. Belloff,
  General Counsel and Corp Secy